Cargando…
Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease
Inflammatory bowel disease (IBD) is a complex, chronic intestinal inflammatory disorder that primarily includes Crohn’s disease (CD) and ulcerative colitis (UC). Although traditional antibiotics and immunosuppressants are known as the most effective and commonly used treatments, some limitations may...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399643/ https://www.ncbi.nlm.nih.gov/pubmed/36032720 http://dx.doi.org/10.3389/fbioe.2022.909591 |
_version_ | 1784772571394211840 |
---|---|
author | Dong, Yumeng Xu, Tiangang Xiao, Guozheng Hu, Ziyan Chen, Jingyu |
author_facet | Dong, Yumeng Xu, Tiangang Xiao, Guozheng Hu, Ziyan Chen, Jingyu |
author_sort | Dong, Yumeng |
collection | PubMed |
description | Inflammatory bowel disease (IBD) is a complex, chronic intestinal inflammatory disorder that primarily includes Crohn’s disease (CD) and ulcerative colitis (UC). Although traditional antibiotics and immunosuppressants are known as the most effective and commonly used treatments, some limitations may be expected, such as limited efficacy in a small number of patients and gut flora disruption. A great many research studies have been done with respect to the etiology of IBD, while the composition of the gut microbiota is suggested as one of the most influential factors. Along with the development of synthetic biology and the continuing clarification of IBD etiology, broader prospects for novel approaches to IBD therapy could be obtained. This study presents an overview of the currently existing treatment options and possible therapeutic targets at the preclinical stage with respect to microbial synthesis technology in biological therapy. This study is highly correlated to the following topics: microbiota-derived metabolites, microRNAs, cell therapy, calreticulin, live biotherapeutic products (LBP), fecal microbiota transplantation (FMT), bacteriophages, engineered bacteria, and their functional secreted synthetic products for IBD medical implementation. Considering microorganisms as the main therapeutic component, as a result, the related clinical trial stability, effectiveness, and safety analysis may be the major challenges for upcoming research. This article strives to provide pharmaceutical researchers and developers with the most up-to-date information for adjuvant medicinal therapies based on synthetic biology. |
format | Online Article Text |
id | pubmed-9399643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93996432022-08-25 Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease Dong, Yumeng Xu, Tiangang Xiao, Guozheng Hu, Ziyan Chen, Jingyu Front Bioeng Biotechnol Bioengineering and Biotechnology Inflammatory bowel disease (IBD) is a complex, chronic intestinal inflammatory disorder that primarily includes Crohn’s disease (CD) and ulcerative colitis (UC). Although traditional antibiotics and immunosuppressants are known as the most effective and commonly used treatments, some limitations may be expected, such as limited efficacy in a small number of patients and gut flora disruption. A great many research studies have been done with respect to the etiology of IBD, while the composition of the gut microbiota is suggested as one of the most influential factors. Along with the development of synthetic biology and the continuing clarification of IBD etiology, broader prospects for novel approaches to IBD therapy could be obtained. This study presents an overview of the currently existing treatment options and possible therapeutic targets at the preclinical stage with respect to microbial synthesis technology in biological therapy. This study is highly correlated to the following topics: microbiota-derived metabolites, microRNAs, cell therapy, calreticulin, live biotherapeutic products (LBP), fecal microbiota transplantation (FMT), bacteriophages, engineered bacteria, and their functional secreted synthetic products for IBD medical implementation. Considering microorganisms as the main therapeutic component, as a result, the related clinical trial stability, effectiveness, and safety analysis may be the major challenges for upcoming research. This article strives to provide pharmaceutical researchers and developers with the most up-to-date information for adjuvant medicinal therapies based on synthetic biology. Frontiers Media S.A. 2022-08-10 /pmc/articles/PMC9399643/ /pubmed/36032720 http://dx.doi.org/10.3389/fbioe.2022.909591 Text en Copyright © 2022 Dong, Xu, Xiao, Hu and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Dong, Yumeng Xu, Tiangang Xiao, Guozheng Hu, Ziyan Chen, Jingyu Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
title | Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
title_full | Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
title_fullStr | Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
title_full_unstemmed | Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
title_short | Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
title_sort | opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399643/ https://www.ncbi.nlm.nih.gov/pubmed/36032720 http://dx.doi.org/10.3389/fbioe.2022.909591 |
work_keys_str_mv | AT dongyumeng opportunitiesandchallengesforsyntheticbiologyinthetherapyofinflammatoryboweldisease AT xutiangang opportunitiesandchallengesforsyntheticbiologyinthetherapyofinflammatoryboweldisease AT xiaoguozheng opportunitiesandchallengesforsyntheticbiologyinthetherapyofinflammatoryboweldisease AT huziyan opportunitiesandchallengesforsyntheticbiologyinthetherapyofinflammatoryboweldisease AT chenjingyu opportunitiesandchallengesforsyntheticbiologyinthetherapyofinflammatoryboweldisease |